Source: Unith
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Unith (ASX:UNT) reported a 100 per cent increase to its investment in AudioStack, formerly known as Aflorithmic Labs
  • The investment partnership with AudioStack, an AI audio content producer, has risen to $3.9 million, from the $2 million valuation reported as of June 30, 2023
  • UNT last traded at 1.5 cents

Unith (ASX:UNT) has revealed a 100 per cent increase in the valuation of its investment in AudioStack, formerly known as Aflorithmic Labs.

The investment partnership with AudioStack, an AI audio content producer, has risen to $3.9 million, from the $2 million valuation reported as of June 30, 2023.

AudioStack has completed a pre-Series A funding round, securing £2.5 million (A$4.1 million), with Quadri Ventures leading the investment.

The funding round was completed at a pre-money valuation of US$27 million (A$41 million) and resulted in an uplifted post-money valuation for Unith’s 9.7 per cent stake in AudioStack.

Unith remains actively engaged in collaboration with AudioStack, serving as AI service provider for the integration of audio technology into the Digital Human platform and its voice library. This aligns with the company’s ongoing efforts outlined in its recently released investor update.

Unith highlighted the soft launch of its platform, enabling the creation of digital humans to support various use cases.

UNT last traded at 1.5 cents.

UNT by the numbers
More From The Market Online

Raiden opens door to private Mallina in win-win Arrow Gold divestment

Raiden Resources has announced its execution of a farm-in deal on-site Raiden's non-core asset, the Arrow…

UNITH’s digital humans expand into Amazon; Facebook

AI-powered 'Digital Human' chatbot developer UNITH has announced its in-house tech can now harmonise with that…
The Market Online Video

Market Update: ASX in a sea of red with energy the only green oasis

The ASX200 is down .8 of a per cent – exceeding future’s predictions by some margin.

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…